{"entity":{"id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SKB103 for injection monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"SKB103 for Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07459998 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 277 participants planned, started 2026-04-23 and due to reach its primary completion in 2029-12-31. Interventions recorded: SKB103 for injection monotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07459998","url":"https://clinicaltrials.gov/study/NCT07459998"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07459998","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB103 for Injection in Participants With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":277,"outcomes":[]},"route":"/trials/nct07459998/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}